Roche Discontinues Development Of NK-1 Antagonist For Depression
This article was originally published in The Pink Sheet Daily
Two Phase II trials for the neurokinin-1 antagonist failed to differentiate between the active controls and placebo, the company says, making it “difficult” to discern a drug effect for the NK-1 agent. Roche will consider out-licensing the product.
You may also be interested in...
The US FDA appears to have concerns about the device used to administer the vaccine.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.